Andrew A. Guirguis

Andrew A. Guirguis

Auto-generated profile, based on publicly available information

Andrew A. Guirguis

Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2020 in Nature
Verified
Journal Article
Closed access
PDF file
MSMikołaj Słabicki
Mikołaj Słabicki
HYHojong Yoon
Hojong Yoon
JKJonas Koeppel
Jonas Koeppel
LNLena Nitsch
Lena Nitsch
SBShourya S. Roy Burman
Shourya S. Roy Burman
BEBenjamin L. Ebert
Benjamin L. Ebert

6 January 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MJMax Jan
Max Jan
ISIrene Scarfò
Irene Scarfò
RLRebecca C. Larson
Rebecca C. Larson
AWAmanda Walker
Amanda Walker
ASAndrea Schmidts
Andrea Schmidts
BEBenjamin L. Ebert
Benjamin L. Ebert
Cell-based therapies are emerging as effective agents against cancer and other diseases. As autonomous “living drugs,” these therapies lack precise control. Chimeric antigen receptor (CAR) T cells effectively target hematologic malignancies but can proliferate rapidly and cause toxicity. We developed ON and OFF switches for CAR T cells using the clinically approved drug lenalidomide, which mediates the proteasomal degradation of several target proteins by inducing interactions between the CRL4 CRBN E3 ubiquitin ligase and a C2H2 zinc finger degron motif. We performed a systematic screen to identify “super-degron” tags with enhanced sensitivity to lenalidomide-induced degradation and used these degradable tags to generate OFF-switch degradable CARs. To create an ON switch, we engineered a lenalidomide-inducible dimerization system and developed split CARs that required both lenalidomide and target antigen for activation. Subtherapeutic lenalidomide concentrations controlled the effector functions of ON- and OFF-switch CAR T cells. In vivo, ON-switch split CARs demonstrated lenalidomide-dependent antitumor activity, and OFF-switch degradable CARs were depleted by drug treatment to limit inflammatory cytokine production while retaining antitumor efficacy. Together, the data showed that these lenalidomide-gated switches are rapid, reversible, and clinically suitable systems to control transgene function in diverse gene- and cell-based therapies.

8 December 2021 in Nature
Verified
Journal Article
Closed access
PDF file
KFKatie A. Fennell
Katie A. Fennell
DVDane Vassiliadis
Dane Vassiliadis
ELEnid Y. N. Lam
Enid Y. N. Lam
LMLuciano G. Martelotto
Luciano G. Martelotto
JBJesse J. Balic
Jesse J. Balic
MDMark A. Dawson
Mark A. Dawson

7 August 2023 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
AGAndrew A. Guirguis
Andrew A. Guirguis
YOYaara Ofir-Rosenfeld
Yaara Ofir-Rosenfeld
KKKathy Knezevic
Kathy Knezevic
WBWesley Blackaby
Wesley Blackaby
DHDavid Hardick
David Hardick
MDMark A. Dawson
Mark A. Dawson
Therapies that enhance antitumor immunity have altered the natural history of many cancers. Consequently, leveraging nonoverlapping mechanisms to increase immunogenicity of cancer cells remains a priority. Using a novel enzymatic inhibitor of the RNA methyl­transferase METTL3, we demonstrate a global decrease in N6-methyladenosine (m6A) results in double-stranded RNA (dsRNA) formation and a profound cell-intrinsic interferon response. Through unbiased CRISPR screens, we establish dsRNA-sensing and interferon signaling are primary mediators that potentiate T-cell killing of cancer cells following METTL3 inhibition. We show in a range of immunocompetent mouse models that although METTL3 inhibition is equally efficacious to anti–PD-1 therapy, the combination has far greater preclinical activity. Using SPLINTR barcoding, we demonstrate that anti–PD-1 therapy and METTL3 inhibition target distinct malignant clones, and the combination of these therapies overcomes clones insensitive to the single agents. These data provide the mole­cular and preclinical rationale for employing METTL3 inhibitors to promote antitumor immunity in the clinic. Significance: This work demonstrates that METTL3 inhibition stimulates a cell-intrinsic interferon response through dsRNA formation. This immunomodulatory mechanism is distinct from current immunotherapeutic agents and provides the molecular rationale for combination with anti–PD-1 immune-checkpoint blockade to augment antitumor immunity. This article is featured in Selected Articles from This Issue, p. 2109

4 October 2018 in Blood
Verified
Journal Article
Open access
PDF file
EFEmma C. Fink
Emma C. Fink
MMMarie McConkey
Marie McConkey
DADylan N. Adams
Dylan N. Adams
SHSaurav D. Haldar
Saurav D. Haldar
JKJames A. Kennedy
James A. Kennedy
BEBenjamin L. Ebert
Benjamin L. Ebert
Key Points: Crbn I391V mice degrade known thalidomide derivative targets and recapitulate thalidomide-induced cytopenias and teratogenicity. Degradation of Ck1α is sufficient to explain the in vivo therapeutic window of lenalidomide in del(5q) myelodysplastic syndrome.

20 September 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
DBDaniel P. Bondeson
Daniel P. Bondeson
ZMZachary Mullin-Bernstein
Zachary Mullin-Bernstein
SOSydney Oliver
Sydney Oliver
TSThomas A. Skipper
Thomas A. Skipper
TAThomas C. Atack
Thomas C. Atack
AIAlessandra Ianari
Alessandra Ianari
Conditional degron tags (CDTs) are a powerful tool for target validation that combines the kinetics and reversible action of pharmacological agents with the generalizability of genetic manipulation. However, successful design of a CDT fusion protein often requires a prolonged, ad hoc cycle of construct design, failure, and re-design. To address this limitation, we report here a system to rapidly compare the activity of five unique CDTs: AID/AID2, IKZF3d, dTAG, HaloTag, and SMASh. We demonstrate the utility of this system against 16 unique protein targets. We find that expression and degradation are highly dependent on the specific CDT, the construct design, and the target. None of the CDTs leads to efficient expression and/or degradation across all targets; however, our systematic approach enables the identification of at least one optimal CDT fusion for each target. To enable the adoption of CDT strategies more broadly, we have made these reagents, and a detailed protocol, available as a community resource.